Debt-to-equity of Kiromic Biopharma, Inc. from 30 Jun 2021 to 31 Dec 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kiromic Biopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 31 Dec 2024.
  • Kiromic Biopharma, Inc. Debt-to-equity for the quarter ending 31 Dec 2024 was -228%, a 21% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Kiromic Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2024 -228% +61% +21% 31 Dec 2024
Q3 2024 -254% +60% +19% 30 Sep 2024
Q2 2024 -298% +61% +17% 30 Jun 2024
Q1 2024 -294% +2921% +91% 31 Mar 2024
Q4 2023 -290% -457% -273% 31 Dec 2023
Q3 2023 -314% -364% -728% 30 Sep 2023
Q2 2023 -360% -379% -1984% 30 Jun 2023
Q1 2023 -3215% -3229% -23594% 31 Mar 2023
Q4 2022 167% +157% +1511% 31 Dec 2022
Q3 2022 50% +40% +404% 30 Sep 2022
Q2 2022 19% -8.2% -30% 30 Jun 2022
Q1 2022 14% 31 Mar 2022
Q4 2021 10% 31 Dec 2021
Q3 2021 9.9% 30 Sep 2021
Q2 2021 27% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.